Phaseline

Targets › GFRA4

GFRA4 (GDNF family receptor alpha-4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2039.

Receptor for persephin (PSPN), a growth factor that exhibits neurotrophic activity on mesencephalic dopaminergic and motor neurons. Acts by binding to its coreceptor, GFRA4, leading to autophosphorylation and activation of the RET receptor. (UniProt, Q9GZZ7)

Open in Phaseline: the race on GFRA4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of PennsylvaniaCART-GFRa4 cells
anti-GFRα4 CAR-T cell therapy with TCRζ/4-1BB co-stimulatory domains
GFRA4Phase 1Metastatic Medullary Thyroid CancerJun 2039

Conditions

Metastatic Medullary Thyroid Cancer (1)

Modalities

mixed (1)

Companies

University of Pennsylvania (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.